Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor

References

• Economou M, Pappas G. New global map of Crohn’s disease: Genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis 2008;14:709–20.
   PubMed Web of Science ®Google Scholar
• Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012;27:1266–80.
   PubMed Web of Science ®Google Scholar
• WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health 2010;18:237.
   PubMedGoogle Scholar
• Bygbjerg IC. Double burden of noncommunicable and infectious diseases in developing countries. Science 2012;337:1499–501.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomized trial. Lancet 2008;371:660–7.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–95.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–104.
   PubMed Web of Science ®Google Scholar
• Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185–206.
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122–7.
   PubMed Web of Science ®Google Scholar
• Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009;60:1884–94.
   PubMed Web of Science ®Google Scholar
• Abreu C, Magro F, Santos-Antunes J, Pilão A, Rodrigues-Pinto E, Bernardes J, et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis 2013;7:e486–92.
   PubMedGoogle Scholar
• Jauregui-Amezaga A, Turon F, Ordás I, Gallego M, Feu F, Ricart E, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis 2013;7:208–12.
   PubMed Web of Science ®Google Scholar
• Debeuckelaere C, De Munter P, Van Bleyenbergh P, De Wever W, Van Assche G, Rutgeerts P, et al. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J Crohns Colitis 2014;8:550–7.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, et al. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis 2014;17:291–8.
   PubMed Web of Science ®Google Scholar
• Lew WJ, Lee EG, Bai JY, Kim HJ, Bai GH, Ahn DI, et al. An Internet-based surveillance system for tuberculosis in Korea. Int J Tuberc Lung Dis 2006;10:1241–7.
   PubMed Web of Science ®Google Scholar
• Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. MEDrang Inc; Seoul: 2011.
   Google Scholar
• Korean Statistical Information Service [2010 Population and Housing Census Wes site]. August 19 2011. Available from https://www.census.go.kr. Accessed 1 June 2014.
   Google Scholar
• Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, et al. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lung 2013;191:565–71.
   PubMed Web of Science ®Google Scholar
• Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61:300–4.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EVJr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19–31.
   PubMed Web of Science ®Google Scholar
• Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadvornova Y, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011;17:77–83.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443–68.
   PubMed Web of Science ®Google Scholar
• Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection - United States. 2010. MMWR Recomm Rep 2010;59:1–25.
   PubMedGoogle Scholar
• Chung KB, Lee EY, Im JP, Han SK, Yim JJ. Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-alpha inhibitor. Korean J Intern Med 2013;28:174–9.
   PubMed Web of Science ®Google Scholar
• Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007;7:328–37.
   PubMed Web of Science ®Google Scholar
• Click ES, Moonan PK, Winston CA, Cowan LS, Oeltmann JE. Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. Clin Infect Dis 2012;54:211–19.
   PubMed Web of Science ®Google Scholar
• Lillebaek T, Kok-Jensen A, Viskum K. Bacillarity at autopsy in pulmonary tuberculosis. Mycobacterium tuberculosis is often disseminated. APMIS 2002;110:625–9.
   PubMed Web of Science ®Google Scholar
• Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49:1–51.
   PubMedGoogle Scholar
• British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800–5.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940–87.
   PubMed Web of Science ®Google Scholar
• Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766–72.
   PubMed Web of Science ®Google Scholar
• American Gastroenterology Association. Adult IBD physician performance measures set [AGA Web site]. October 26 2011. Available from http://www.gastro.org/practice/quality-initiatives/IBD_Measures.pdf. Assessed 12 September 2014.
   Google Scholar
• Melmed GY, Siegel CA, Spiegel BM, Allen JI, Cima R, Colombel JF, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis 2013;19:662–8.
   PubMed Web of Science ®Google Scholar
• Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis 2012;18:1057–63.
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EVJr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929–36.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012;107:1409–22.
   PubMed Web of Science ®Google Scholar